

PATENT
ATTORNEY DOCKET NO.: 95-02ABB
Customer No.: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Tse Wen Chang

Serial No.: 10/005,438

Filed: December 3, 2001

For: HYBRID WITH INTERFERON- α
AND AN IMMUNOGLOBULIN Fc FOR
TREATMENT OF TUMORS

)
)
)
) Group Art Unit: 1642
)
)
) Examiner: S. Ungar
)
)
)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants submit the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were supplied in the parent application.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO 1449 form.

This submission does not represent that a search has been made or that no other documents exist which may be material to the examination of this application and does not constitute an admission that any of the listed documents, or any part thereof,

Application No.: 10/005,438
Attorney Docket No.: TNX95-02ABB
Customer No.: 26839

are material or constitute prior art under title 35 of the United States code. If the Examiner applies any of the documents as prior art against any claim in the application, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents should the Applicant(s) determine(s) that the cited document(s) do not constitute "prior art".

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully Submitted,

Dated: March 20, 2002.

BY: Cheryl A. Liljestrand
Cheryl A. Liljestrand
Reg. No. 45,275

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

1

OF

5

Complete if Known

Application Number - 10/005,438

Filing Date - Dec. 3, 2001

First Named Inventor - Tso Wen Chang

Group Art Unit - 1642

Examiner Name - S. UNGAR

Attorney Docket Number TNX95-2ABB

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
	4973478	B1	Gauldia, et al.	05/24/1989	
	5004805	B1	Hershenson, et al.	04/02/1991	
	5460811	B1	Goeddel, et al.	10/24/1995	
	5468809	B1	Reval, et al.	11/21/1995	
	5468808	B1	Reval, et al.	11/21/1995	
	5468807	B1	Reval, et al.	11/21/1995	

FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				
	EP	0083089	B1	Itoh, et al.	08/11/1987		
	EP	0084681	A2	Taniguchi, et al.	11/17/1982		
	EP	0467416	A1	Bumelt, et al.	01/22/1992		
	WO	9118353	A1	Leroche, et al.	10/31/1991		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 2 OF 5**Complete if Known**

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor - Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
	5015730	B1	Friesen, et al.	05/14/1991	
	4289659	B1	Friesen, et al.	09/15/1981	
	5428130	B1	Capon, et al.	06/27/1995	
	5349053	B1	Landolfi	09/20/1994	

FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

3

OF

5

Complete if Known

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ₂
		Huston, JS, <i>et al.</i> , <i>Methods in Enzymology</i> , 203:46-88.	
		Landolfi, N.F., <i>J. Immunol</i> , 146:915-919 (1991), Chimeric IL-2/Ig Molecule.	
		Peterhans, A., <i>et al.</i> , <i>Analytical Biochemistry</i> , 163(2) 470-75.	
		Baron, E. and Narula S., <i>Biotechnology</i> , 10:179-190, 1990, From cloning to a commercial realization: Human alpha interferon.	
		Bocci, V., <i>Interferon</i> , 4:47-72, 1985, Distribution, catabolism and pharmacokinetics of interferons.	
		Bohoslawec, O. <i>et al.</i> , <i>J. Interferon Res.</i> , 6:207-213, 1986, Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in Mice.	
		Bonetti, A. and Kim, S. <i>Cancer Chemother Pharmacol.</i> 33:258-261, 1993, Pharmacokinetics of an extended-release human interferon alpha-2b formulation.	
		Brown, K.D. <i>Genetic Engineering News</i> , 15:1-35, 1995, Novel emerging therapeutics target the hepatitis C virus.	
		Brunt, J.V., <i>Biotechnology</i> , 7:549, 1989, Interferon trials proliferate.	
		Cantell, K. <i>et al.</i> , <i>Methods in Enzymology</i> , 78A:29-38, Academic Press, 1981.	
		Coligan, J.E. <i>et al.</i> , <i>Current Protocols in Immunology</i> , pp 6.9.1-6.9.8, Current Protocols, 1991, Measurement of antiviral activity induced by interferon α , β , and γ .	
		Daugherty, B.L. <i>et al.</i> , <i>Nucleic Acids Res.</i> 19:2471-6, 1991, Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins.	
		Dianzani, F. <i>J. Interferon Res.</i> (Special Issue) 109-118, 1992, Interferon treatments: how to use an endogenous system as a therapeutic agent.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

4

OF

5

Complete if Known

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1842

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s).	T 2
		Evinger, M. and Pestka, S., <i>Methods in Enzymology</i> , 79:362-8, Assay of growth inhibition in lymphoblastoid cell cultures.	
		Goeddel, D.V. <i>et al.</i> , <i>Nature</i> , 290:20-26, 1981, The structure of eight distinct cloned human leukocyte interferon dDNAs	
		Guterman, J., <i>Proc. Nat. Aca. Sci.</i> 91:1198-1205;1994, Cytokine therapeutics: lessons from interferon α .	
		Johns, T.G. <i>et al.</i> , <i>Cancer Res.</i> , 50:4718-23, 1990, Pharmacokinetics, tissue distribution, and cell localization of [35 S] methionine-labeled recombinant human and murine α interferons in mice.	
		Kabat, E.A. <i>et al.</i> , <i>Sequences of proteins of Immunological Interest</i> , pp 1582-98, NIH, 1991	
		Kurschner, C. <i>et al.</i> , <i>J. Immunol.</i> 149:4096-4100, 1992, IFN- γ receptor-Ig fusion proteins.	
		Mordenti, J. <i>et al.</i> , <i>Nature</i> , 337:525-31, 1989, Designing CD4 immunoadhesins for AIDS therapy.	
		Quesada, J.R. <i>et al.</i> , <i>J. Clin. Oncol.</i> 4:234-243, 1986, Clinical toxicity of interferons in cancer patients: a review	
		Roche Labs, Referon A, Schering, Intron A, <i>Physicians' Desk Reference</i> , 47 edition, 1993, pp. 2006-2008, 2194-2201.	
		Roitt, I., <i>Essential Immunology</i> , 7 th edition, 1991, Blackwell Scientific Publications, pp. 45-51, Immunoglobulin classes and subclasses.	
		Saiki, R.K. <i>et al.</i> , <i>Science</i> , 239:487, 1988, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.	
		Sambrook, J. <i>et al.</i> , <i>Molecular cloning</i> , 1989, Cold Spring Harbor Laboratory Press, pp. 16.28-16.29.	
		Schein, C.H. and Nøtved, H.M., <i>Bio/technology</i> , 6:291-294, 1988, Formation of soluble recombinant proteins in <i>Escherichia coli</i> is favored by lower growth temperature.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

5

OF

5

Complete if Known

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s).	T 2
		Scorer, C.A. <i>et al.</i> , <i>Gene</i> , 138:111-9, 1993, The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast <i>Pichia pastoris</i> .	
		Strander, H. <i>Adv. Cancer Res.</i> 46:1-265, 1986, Interferon treatment of human neoplasia.	
		Tabata, Y. <i>et al.</i> , <i>Cancer Res.</i> 51:5532-8, 1991, Effects of recombinant alpha-Interferon-gelatin conjugate on in vivo murine tumor cell growth.	
		Von Gabain, A., <i>et al.</i> , <i>Eur. J. Biochem.</i> 190:257-61, 1990, Three human interferon- α 2 subvariants disclose structural and functional differences.	
		Weissmann, C. and Weber, H. <i>Prog. Nuc. Acid Res. Mol. Biol.</i> 33:251-300, 1986, The interferon genes.	
		Wilkinson, D.L. and Harrison, R.G., <i>Bio/technology</i> , 9:443-448, 1991, Predicting the solubility of recombinant proteins in <i>Escherchia coll.</i>	
		Zoon, K.C. <i>Interferon</i> , 9:1-12, 1987, Human interferons: structure and function.	
		Physicians' Desk Reference 2194-2201	
		Capon, D. <i>et al.</i> , <i>Nature</i> , 337:525-531, 1989, Designing CD4 Immuno adhesions for AIDS Therapy	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.